IMS Health to acquire competitor SDI Health

IMS Health said it signed a definitive agreement to acquire privately held insight and analytics company SDI Health, bringing together two of the largest pharmaceutical marketing research firms. Financial terms of the deal were not disclosed.
Both companies declined to discuss the acquisition beyond a joint statement released last month. Unnamed company sources told Ed Silverman, who first reported the deal on his Pharmalot blog, that as much as 15% of SDI staff could lose their jobs as a result of the acquisition.
Like IMS, SDI provides prescription data. It also tracks a robust set of promotional information, including pharma company spending on detailing, meetings and events and ePromotion activities.
“The acquisition will enable more robust patient and specialty analytics, and will give IMS the ability to provide a broader set of stakeholders with clinically rich insights from all healthcare channels, including hospitals, providers and pharmacies,” the joint statement said. “The addition of SDI's complementary information assets and capabilities positions IMS to improve existing offerings, fuel new investments and deliver greater innovation and value to a healthcare industry that is seeking to drive increased efficiencies as a result of significant, ongoing pressure to reduce costs and expand patient access.”
Gary Gatyas, an IMS Health spokesperson, declined to speculate on timing for the completion of the deal, citing pre-merger notification requirements with respect to the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.